Larimar Therapeutics (LRMR) Amortization of Deferred Charges (2015 - 2016)
Larimar Therapeutics' (LRMR) quarterly Amortization of Deferred Charges came in at $10000.0 in Q4 2016, down 28.57% on a YoY basis from $14000.0 in Q1 2016, and up 11.11% quarter-over-quarter from $9000.0 in Q3 2016.
Powered by 
Analysis
Larimar Therapeutics (LRMR) Amortization of Deferred Charges (2015 - 2016) Analysis & Trends
Larimar Therapeutics (LRMR) has reported Amortization of Deferred Charges for 2 consecutive years, with $10000.0 the latest figure, recorded in Q4 2016.
- For the quarter ending Q4 2016, Amortization of Deferred Charges fell 28.57% year-over-year to $10000.0; the trailing twelve-month figure through Dec 2016 stood at $43000.0 (down 30.65% YoY), and the FY2016 full-year result was $43000.0, down 30.65% from the prior year.
- Amortization of Deferred Charges grew to $10000.0 in Q4 2016 per LRMR's latest filing, from $9000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $17000.0 in Q2 2015 and bottomed at $9000.0 in Q3 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2016 | 10,000.00 |
| Sep 30, 2016 | 9,000.00 |
| Jun 30, 2016 | 11,000.00 |
| Mar 31, 2016 | 13,000.00 |
| Dec 31, 2015 | 14,000.00 |
| Sep 30, 2015 | 15,000.00 |
| Jun 30, 2015 | 17,000.00 |
| Mar 31, 2015 | 16,000.00 |